CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 1986; 36:42-47
doi: 10.3322/canjclin.36.1.42
© 1986 American Cancer Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

CA: A Cancer Journal for Clinicians, Vol 36, 42-47, Copyright © 1986 by American Cancer Society

National Institutes of Health Consensus Development Conference Statement: Adjuvant Chemotherapy for Breast Cancer. September 9-11, 1985

Adjuvant chemotherapy and hormonal therapy are effective treatments for breast cancer patients. While significant advances have been made in the past five years, optimal therapy has not been defined for any subset of patients. For this reason, all patients and their physicians are strongly encouraged to participate in controlled clinical trials.

Outside the context of a clinical trial and based on the research data presented at the 1985 Consensus Development Conference, the following statements can be made:

• For premenopausal women with positive nodes, regardless of hormone receptor status, treatment with established combination chemotherapy should become standard care.

• For premenopausal women with negative nodes, adjuvant therapy is not generally recommended. For certain high-risk patients in this group, adjuvant chemotherapy should be considered.

• For postmenopausal women with positive nodes and positive hormone receptor levels, tamoxifen is the treatment of choice.

• For postmenopausal women with positive nodes and negative hormone receptor levels, chemotherapy may be considered but cannot be recommended as standard practice.

• For postmenopausal women with negative nodes, regardless of hormone receptor levels, there is no indication for routine adjuvant treatment. For certain high-risk patients in this group, adjuvant therapy may be considered.




This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
J. L. Warren, K. R. Yabroff, A. Meekins, M. Topor, E. B. Lamont, and M. L. Brown
Evaluation of Trends in the Cost of Initial Cancer Treatment
J Natl Cancer Inst, June 18, 2008; 100(12): 888 - 897.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. Jatoi, B. E. Chen, W. F. Anderson, and P. S. Rosenberg
Breast Cancer Mortality Trends in the United States According to Estrogen Receptor Status and Age at Diagnosis
J. Clin. Oncol., May 1, 2007; 25(13): 1683 - 1690.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
E. J. Feuer
Chapter 1: Modeling the Impact of Adjuvant Therapy and Screening Mammography on U.S. Breast Cancer Mortality Between 1975 and 2000: Introduction to the Problem
J Natl Cancer Inst Monographs, October 1, 2006; 2006(36): 2 - 6.
[Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
A. B. Mariotto, E. J. Feuer, L. C. Harlan, and J. Abrams
Chapter 2: Dissemination of Adjuvant Multiagent Chemotherapy and Tamoxifen for Breast Cancer in the United States Using Estrogen Receptor Information: 1975-1999
J Natl Cancer Inst Monographs, October 1, 2006; 2006(36): 7 - 15.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
B. K. Edwards, M. L. Brown, P. A. Wingo, H. L. Howe, E. Ward, L. A. G. Ries, D. Schrag, P. M. Jamison, A. Jemal, X. C. Wu, et al.
Annual Report to the Nation on the Status of Cancer, 1975-2002, Featuring Population-Based Trends in Cancer Treatment
J Natl Cancer Inst, October 5, 2005; 97(19): 1407 - 1427.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. Mariotto, E. J. Feuer, L. C. Harlan, L.-M. Wun, K. A. Johnson, and J. Abrams
Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975-1999
J Natl Cancer Inst, November 6, 2002; 94(21): 1626 - 1634.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. C. Harlan, J. Abrams, J. L. Warren, L. Clegg, J. Stevens, and R. Ballard-Barbash
Adjuvant Therapy for Breast Cancer: Practice Patterns of Community Physicians
J. Clin. Oncol., April 1, 2002; 20(7): 1809 - 1817.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
National Institutes of Health Consensus Developmen
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 5 - 15.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
W. C. Wood
Adjuvant Therapy for Breast Cancer: Current Controversies and Future Prospects
J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 16 - 16.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
J Natl Cancer Inst, July 4, 2001; 93(13): 979 - 989.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by American Cancer Society.